{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T10:53:42Z","timestamp":1721472822921},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.023","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S272-S279","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S3","title":["Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure"],"prefix":"10.3816","volume":"9","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.023_bib1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: implications for imatinib therapy","volume":"44","author":"Alvarez","year":"2007","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2009.s.023_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.023_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.023_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.3816\/CLM.2009.s.023_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.3816\/CLM.2009.s.023_bib6","author":"Novartis Pharmaceuticals Corporation"},{"key":"10.3816\/CLM.2009.s.023_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2009.s.023_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.023_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.023_bib10","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib11","doi-asserted-by":"crossref","first-page":"580a","DOI":"10.1182\/blood.V110.11.1951.1951","article-title":"Imatinib resistance and\/or intolerance in clinical practice in Europe. The \u201cUnmet Needs in CML and Ph+ ALL\u201d (UNIC) study","volume":"110","author":"Michallet","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib12","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'hare","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","article-title":"An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy","volume":"10","author":"Laudadio","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.3816\/CLM.2009.s.023_bib14","author":"Bristol-Myers Squibb Company"},{"key":"10.3816\/CLM.2009.s.023_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.023_bib17","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib20","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.023_bib22","author":"National Comprehensive Cancer Network (NCCN)"},{"key":"10.3816\/CLM.2009.s.023_bib23","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2009.s.023_bib24","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.3816\/CLM.2009.s.023_bib26","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib27","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib28","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib29","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib30","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib31","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib32","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib33","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib34","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"suppl 2","key":"10.3816\/CLM.2009.s.023_bib35","first-page":"0356a","article-title":"Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations","volume":"92","author":"Mueller","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib36","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.023_bib38","first-page":"226a","article-title":"Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinibresistance or intolerance","volume":"110","author":"Kantajarian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib39","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib40","doi-asserted-by":"crossref","first-page":"101a","DOI":"10.1182\/blood.V110.11.320.320","article-title":"Responses and disease progression in CMLCP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types","volume":"110","author":"Hughes","year":"2007","journal-title":"Blood"},{"issue":"suppl 2","key":"10.3816\/CLM.2009.s.023_bib41","first-page":"0904a","article-title":"The P-loop mutations Y253H and E255K\/V may develop more frequently than T3151 during nilotinib therapy after imatinib failure and are associated with progression in patients with Ph-positive leukemia","volume":"92","author":"Branford","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.12186","article-title":"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib","volume":"93","author":"La Rosee","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib43","first-page":"577a","article-title":"Event-free survival in patients (pts) with chronic myeloid leukemia (CML) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure is dependent on the in vitro sensitivity of BCR-ABL kinase domain (KD) mutations","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib44","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib45","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib47","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib48","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib49","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib50","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib51","first-page":"225a","article-title":"Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ Chronic Myelogenous Leukemia (CML)","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib52","first-page":"358s","article-title":"Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib","volume":"25","author":"Gambacorti-Passerini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib53","doi-asserted-by":"crossref","first-page":"376s","DOI":"10.1200\/jco.2008.26.15_suppl.7018","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors","volume":"26","author":"Pinilla-Ibarz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib54","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","article-title":"The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation","volume":"72","author":"Rahmani","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.3816\/CLM.2009.s.023_bib56","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib57","doi-asserted-by":"crossref","first-page":"312a","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib59","first-page":"243a","article-title":"MK-0457 is a novel aurora kinase and janus kinase 2 inhibitor with activity in transformed JAK2-positive myeloproliferative disease","volume":"92","author":"Giles","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dof.2007.032.04.1094476","article-title":"Panobinostat. Histone deacetylase (HDAC) inhibitor, apoptosis inducer, oncolytic","volume":"32","author":"Revill","year":"2007","journal-title":"Drugs Future"},{"key":"10.3816\/CLM.2009.s.023_bib62","doi-asserted-by":"crossref","first-page":"276a","DOI":"10.1182\/blood.V110.11.907.907","article-title":"Phase IA\/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies","volume":"110","author":"Spencer","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib63","doi-asserted-by":"crossref","first-page":"315a","DOI":"10.1182\/blood.V110.11.1041.1041","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate","volume":"110","author":"Dai","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib65","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-07-0835","article-title":"Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation","volume":"13","author":"Dasmahapatra","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib66","first-page":"373s","article-title":"A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia","volume":"25","author":"Kadia","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib67","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib68","doi-asserted-by":"crossref","first-page":"312a","DOI":"10.1182\/blood.V110.11.1031.1031","article-title":"Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib","volume":"110","author":"Strauss","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib69","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","article-title":"Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336","volume":"100","author":"Hoover","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib70","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.023_bib71","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.023_bib73","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.023_bib74","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","article-title":"Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia","volume":"94","author":"O'Brien","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.023_bib75","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.11620","article-title":"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.023_bib76","doi-asserted-by":"crossref","first-page":"377s","DOI":"10.1200\/jco.2008.26.15_suppl.7021","article-title":"Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation","volume":"26","author":"Benichou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.023_bib77","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation","volume":"110","author":"de Lavallade","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib78","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2007-08-107482","article-title":"Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia","volume":"111","author":"Deenik","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.s.023_bib80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.023_bib81","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","article-title":"Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib","volume":"11","author":"O'Hare","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.023_bib82","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.023_bib83","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib84","first-page":"934a","article-title":"Dasatinib long-term efficacy in patietns with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C Study","volume":"93","author":"Cervantes","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib85","doi-asserted-by":"crossref","first-page":"374s","DOI":"10.1200\/jco.2008.26.15_suppl.7010","article-title":"Nilotinib in patients with imatinibresistant or -intolerant chronic myelogenous leukemia in chronic phase (CMLCP): Updated phase II results","volume":"26","author":"Kantarjian","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib86","article-title":"Dasatinib efficacy in patients with imatinibresistant\/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A","volume":"93","author":"Rea","year":"2008","journal-title":"Haematologica"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib87","article-title":"Dasatinib efficacy in patients with imatinibresistant\/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program","volume":"93","author":"Saglio","year":"2008","journal-title":"Haematologica"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib88","article-title":"Dasatinib efficacy in patients with imatinibresistant\/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L","volume":"93","author":"Porkka","year":"2008","journal-title":"Haematologica"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.023_bib89","article-title":"A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase","volume":"92","author":"le Coutre","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.023_bib90","unstructured":"ClinicalTrials.gov [Web site]. Available at URL: http:\/\/www.clinicaltrials.gov"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:17Z","timestamp":1590162437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":89,"alternative-id":["S1557919011703511"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.023","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}